Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Proportion of Patients Successfully Inducted to Receive Naltrexone Injection
研究概览
简要总结
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy.
详细描述
The study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy. Lorcaserin or placebo 10 mg bid will be started on Day 1 of the study to address acute withdrawal, then maintained over the next 5 weeks, and stopped after the second XR-naltrexone is administered. Patients will be seen twice weekly for monitoring and offered two injections of naltrexone; at the end of oral naltrexone induction (end of week 1) and four weeks later (week 5). The primary outcome measures will be the proportion of patients successfully inducted onto XR-naltrexone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals between the ages of 18-60
- •Meets DSM-5 criteria of current opioid use disorder present for at least six months, supported by a positive urine for opioids
- •Seeking treatment for opioid use disorder
- •Capable of giving informed consent and complying with study procedures
- •Not underweight; defined as BMI≥18.5
排除标准
- •Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
- •Current DSM-5 criteria for any other psychiatric disorder that in the investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require pharmacotherapy or psychotherapy during the study period. Concurrent treatment with other psychotropic medication is exclusionary.
- •Individuals who meet DSM-5 criteria for any substance use disorders - severe, other than opioid and nicotine use disorder. Physiological dependence on alcohol or sedative-hypnotics is exclusionary.
- •A recent history of binge-use of alcohol or sedative-hypnotics (using large amounts in a short time to severe intoxication or blackouts).
- •Pregnancy, lactation, or failure to use adequate contraceptive method in female patients who are currently engaging in sexual activity with men.
- •Unstable medical conditions, such as AIDS, cancer, uncontrolled hypertension (blood pressure > 140/90), uncontrolled diabetes, pulmonary hypertension or heart disease.
- •Legally mandated to participate in a substance use disorder treatment program.
- •Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide
- •Currently meets DSM-5 diagnosis for an eating disorder with low body weight (BMI <20)
- •History of accidental opioid overdose in the last three years or any other significant history of overdose following detoxification within past 10 years defined as an episode of opioid-induced unconsciousness, whether or not medical treatment was sought or received.
- •Elevated liver function tests (AST and ALT > 3 times the upper limit of normal) or impaired renal function (GFR<60 ml/min)
- •Known history of allergy, intolerance, or hypersensitivity to lorcaserin, naltrexone or any other study medications
- •Concurrent use of migraine medications containing ergotamine (Cafergot, Ergomar) or dihydroergotamine (Migranal), 5HT2B receptor agonists like cabergoline, or medications metabolized by CYP2D6 (thioridazine, tamoxifen, metoprolol, aripiprazole, codeine)
研究组 & 干预措施
Lorcaserin
10 mg capsule taken twice daily of lorcaserin
干预措施: Lorcaserin (Drug)
Placebo
a placebo comparator capsule taken twice daily
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of Patients Successfully Inducted to Receive Naltrexone Injection
时间窗: Study week 1
proportion of individuals who were successfully inducted and received the first XR-naltrexone injection
次要结局
未报告次要终点
研究者
Frances R Levin
Director of Substance Use Disorder
New York State Psychiatric Institute